150 related articles for article (PubMed ID: 10512503)
1. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction.
Elliott WJ; Weir DR
Am J Health Syst Pharm; 1999 Sep; 56(17):1726-32. PubMed ID: 10512503
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of statins.
Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study.
Hilleman DE; Heineman SM; Foral PA
Pharmacotherapy; 2000 Jul; 20(7):819-22. PubMed ID: 10907971
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Martens LL; Guibert R
Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
Grover SA; Coupal L; Paquet S; Zowall H
Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
10. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Maclaine GD; Patel H
Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
Jacobson TA
Am J Cardiol; 1996 Sep; 78(6A):32-41. PubMed ID: 8875973
[TBL] [Abstract][Full Text] [Related]
15. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
16. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
Perreault S; Hamilton VH; Lavoie F; Grover S
Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
[TBL] [Abstract][Full Text] [Related]
17. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
[TBL] [Abstract][Full Text] [Related]
19. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
20. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
